Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02387801 · ClinicalTrials.gov registry record · Phase 3
A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
A Phase 3 study of Psoriasis, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT02387801 is a Phase 3 study of Psoriasis that has completed, run by Eli Lilly and Company. The registered enrollment target is 12 participants, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02387801, a Phase 3 study of Psoriasis, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
To detect onset of activity of ixekizumab in participants with moderate-to-severe plaque psoriasis and to document the same using sequential photographic images.
Conditions Studied
Interventions
- DRUG Ixekizumab
Study Locations (1)
New York
- Mount Sinai School of Medicine Dermatology Clinical Trials - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02387801
The ClinicalTrials.gov registry entry for NCT02387801 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (98% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Ixekizumab is the first listed.
NCT02387801 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02387801 about?
NCT02387801 is a clinical study titled "A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis". To detect onset of activity of ixekizumab in participants with moderate-to-severe plaque psoriasis and to document the same using sequential photographic images.
What is the current status of trial NCT02387801?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2015-04. Estimated completion is 2016-08.
What conditions does trial NCT02387801 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT02387801?
The interventions under investigation include: Ixekizumab (DRUG).
Who is sponsoring clinical trial NCT02387801?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02387801 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.